HHS Rebate Reform: An Air Of Inevitability In Stakeholder Comments
Manufacturers, pharmacy benefit managers and insurers weigh in on the Trump administration’s most significant drug pricing action to date – the HHS Office of Inspector General's proposed rule aimed at eliminating rebates.
You may also be interested in...
Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.
Medicare Trustees Report highlights importance of rebates in Part D but does not address potential changes to system; charts detail the growing impact rebates are expected to have in coming years.
The proposal to eliminate rebates in the US raises important follow up questions, including who will be responsible for pharmacy transactions at the point of sale. PBMs say they should stay in that role to assure a smooth transition; independent pharmacies have other ideas.